Tafasitamab Combination Provides Prolonged, Durable Response in Patients with Aggressive DLBCL

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

Related Keywords

Orlando ,Florida ,United States ,University Hospital ,American ,Tim Demuth ,Steven Stein ,Johannes Duell ,American Association For Cancer Research ,Morphosys Us Inc ,American Association ,Cancer Research ,Annual Meeting ,Medical Clinic ,